Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced its quarterly earnings results on Thursday. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.23, MarketWatch Earnings reports.
NASDAQ:ZYNE traded down $0.44 during trading hours on Friday, hitting $5.95. 339,986 shares of the stock were exchanged, compared to its average volume of 402,426. Zynerba Pharmaceuticals has a 52-week low of $5.03 and a 52-week high of $15.14. The firm has a market cap of $102.22 million, a P/E ratio of -2.40 and a beta of 4.49.
Several equities analysts recently weighed in on the company. HC Wainwright set a $23.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 13th. Canaccord Genuity set a $18.00 price target on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 13th. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. Cantor Fitzgerald assumed coverage on Zynerba Pharmaceuticals in a research note on Friday, September 21st. They issued an “overweight” rating and a $21.00 price target for the company. Finally, ValuEngine lowered Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $18.93.
In other news, Director John P. Butler acquired 5,000 shares of the business’s stock in a transaction on Wednesday, August 22nd. The stock was bought at an average cost of $6.43 per share, for a total transaction of $32,150.00. Following the purchase, the director now owns 5,000 shares in the company, valued at $32,150. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.67% of the stock is currently owned by insiders.
WARNING: This article was posted by Macon Daily and is the sole property of of Macon Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://macondaily.com/2018/11/09/zynerba-pharmaceuticals-zyne-releases-quarterly-earnings-results-beats-estimates-by-0-23-eps.html.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
See Also: Cost of Capital
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.